AbbVie (ABBV) Gains from Sales and Divestitures (2013 - 2016)

AbbVie (ABBV) has 4 years of Gains from Sales and Divestitures data on file, last reported at $6.1 million in Q2 2016.

• Gains from Sales and Divestitures for Q2 2016 came in at $6.1 million, up 11.16% year-over-year; the trailing twelve-month figure through Jun 2016 was $6.1 million (up 11.16% YoY), and the FY2015 annual result was $5.7 million, down 14.1% from the prior year.
• Gains from Sales and Divestitures climbed to $6.1 million in Q2 2016 per ABBV's latest filing, from $5.5 million in the prior quarter.
• Over five years, Gains from Sales and Divestitures peaked at $7.6 million in Q4 2013 and troughed at $5.3 million in Q1 2015.
• A 4-year average of $6.4 million and a median of $6.3 million in 2014 frame the typical range for Gains from Sales and Divestitures.
• The sharpest annual moves came in 2015 and 2016: Gains from Sales and Divestitures dropped 14.53% in 2015, then gained 11.16% in 2016.
• A 4-year view of Gains from Sales and Divestitures shows it stood at $7.6 million in 2013, then decreased by 12.11% to $6.6 million in 2014, then decreased by 14.1% to $5.7 million in 2015, then advanced by 7.65% to $6.1 million in 2016.
• Business Quant data shows ABBV's Gains from Sales and Divestitures at $6.1 million in Q2 2016, $5.5 million in Q1 2016, and $5.7 million in Q4 2015.